Sharon Hutchinson is a Professor of Epidemiology and Population Health at Glasgow Caledonian University and a Consultant at Public Health Scotland. She leads a programme of surveillance and research on hepatitis C and other blood-borne viruses. Her research has provided the key evidence to inform Scotland’s response to hepatitis C.

Oluwaseun Falade-Nwulia, MBBS, MPH is an Associate Professor of Medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine. Her research focuses on developing and evaluating novel strategies to increase engagement in treatments for HCV/HIV prevention and treatment including the integration of substance use care.

Dr. Kimberly Page, Ph.D., MPH is an infectious disease epidemiologist whose research has focused on hepatitis C virus (HCV) and HIV infections in multiple high risk populations. She has led prospective cohort studies, clinical trials and implementation science research. She is a Professor of Epidemiology, Biostatistics and Preventive Medicine, in the Department of Internal Medicine at the University of New Mexico Health Sciences Center. She received her Ph.D. from University of California at Berkeley, and was a faculty member at University of California San Francisco for twenty years before relocating home to New Mexico. She co-led the first HCV vaccine trial, including sites in San Francisco and Albuquerque. Dr. Page currently leads the NIDA Southwest Clinical Trials Network Node based at the University of New Mexico, which aims to advance NIDA’s goals of expanding and research and infrastructure to conduct rapid, multi-site studies of promising science-based therapies and the treatment delivery to patients with substance use disorders in a variety of treatment settings and with diverse populations. Dr. Page is committed to public health and hopes to help with the next HCV vaccine trial!